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Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic
Syndrome in a West African Population
Nuri Kodaman, PhD; Melinda C. Aldrich, PhD; Rafal Sobota, PhD; Folkert W. Asselbergs, MD, PhD; Nancy J. Brown, MD;
Jason H. Moore, PhD; Scott M. Williams, PhD
Background-—Metabolic syndrome (MetS) is diagnosed by the presence of at least 3 of the following: obesity, hypertension,
hyperglycemia, hypertriglyceridemia, and low high-density lipoprotein. Individuals with MetS also typically have elevated plasma
levels of the antiﬁbrinolytic factor, plasminogen activator inhibitor-1 (PAI-1), but the relationships between PAI-1 and MetS
diagnostic criteria are not clear. Understanding these relationships can elucidate the relevance of MetS to cardiovascular disease
risk, because PAI-1 is associated with ischemic events and directly involved in thrombosis.
Methods and Results-—In a cross-sectional analysis of 2220 Ghanaian men and women from urban and rural locales, we found the
age-standardized prevalence of MetS to be as high as 21.4% (urban women). PAI-1 level increased exponentially as the number of
diagnostic criteria increased linearly (P<1013), supporting the conclusion that MetS components have a joint effect that is
stronger than their additive contributions. Body mass index, triglycerides, and fasting glucose were more strongly correlated with
PAI-1 than with canonical MetS criteria, and this pattern did not change when pair-wise correlations were conditioned on all other
risk factors, supporting an independent role for PAI-1 in MetS. Finally, whereas the correlations between conventional risk factors
did not vary signiﬁcantly by sex or across urban and rural environments, correlations with PAI-1 were generally stronger among
urban participants.
Conclusions-—MetS prevalence in the West African population we studied was comparable to that of the industrialized West. PAI-1
may serve as a key link between MetS, as currently deﬁned, and the endpoints with which it is associated. Whether this association
is generalizable will require follow-up. ( J Am Heart Assoc. 2016;5:e003867 doi: 10.1161/JAHA.116.003867)
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M etabolic syndrome (MetS) is a set of cardiometabolicabnormalities that cluster in people at increased risk
for coronary heart disease and type 2 diabetes mellitus. Any 3
of the cardiovascular risk factors of obesity, hypertension,
hyperglycemia, hypertriglyceridemia, and low high-density
lipoprotein (HDL) are sufﬁcient for diagnosis of MetS,
according to a recent consensus statement.1 Although it is
well known that these risk factors co-occur more often than
expected by chance, the reasons for their co-occurrence are
not clear. The implications are also unclear, with recent
debate centered on whether multiple risk factors have a joint
effect on cardiovascular risk greater than the sum of their
individual contributions.2–4 If the increased risk attributed to
MetS can be wholly accounted for by the additive contribu-
tions of its component conditions, arguably little can be
gained by studying the risk factors collectively.
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There is, however, at least 1 aspect of the syndrome that
may distinguish it from its component conditions: Patients
diagnosed with MetS typically suffer from a hypercoagulable
condition of the blood, caused by supranormal levels of
clotting and antiﬁbrinolytic factors.5,6 Among the most
prominent of these factors is plasminogen activator inhibitor
1 (PAI-1), which hinders clot degradation by inhibiting
plasminogen activators in the ﬁbrinolytic pathway.7 PAI-1
appears to be connected to MetS in multiple ways beyond this
antiﬁbrinolytic role. For example, at high levels, PAI-1
promotes a chronic state of low-grade inﬂammation, one of
the proposed underlying causes of MetS.8,9 A number of
proinﬂammatory factors are known to stimulate PAI-1
production, including interleukins, tumor necrosis factor
alpha, transforming growth factor beta, and C-reactive
protein.7,10,11 Although circulating PAI-1 is mainly released
by hepatic and endothelial cells, adipose tissue becomes a
major source as visceral adiposity increases, which also has
been implicated in increased inﬂammation and coronary heart
disease.12,13 High PAI-1 may also predispose patients to
premature atherosclerosis not only through inﬂammatory
pathways, but also by interfering with cell migration.13,14
Other PAI-1 stimulants related to MetS include plasma
glucose, insulin, very low-density lipoprotein (VLDL) choles-
terol, and the vasopressive hormone, angiotensin II.15,16
Perhaps, most important, PAI-1 represents a natural link
between MetS risk factors and acute phases of cardiovascular
disease.16,17 Circadian spikes in PAI-1 levels likely explain the
morning peak in the incidence of myocardial infarction and
stroke,18 and epidemiological studies have demonstrated a
positive association between elevated plasma PAI-1 levels and
adverse cardiovascular events.7,15,19 Thus, understanding how
PAI-1 levels respond to the risk factors of MetS (and vice
versa) should provide insight into how the components of the
syndrome individually—and jointly—increase the risk of
cardiovascular disease.
There have been relatively few studies of MetS in West
Africa, and no large study, to our knowledge, has addressed
the association between PAI-1 and MetS in the region.
Prevalence and etiology of MetS, including its relationship
with PAI-1, vary among ethnic groups,20,21 making it impor-
tant to study these factors simultaneously in different
populations. In addition, urbanization and the changes that
accompany it, such as the adoption of sedentary lifestyle and
nutrient-poor, calorie-rich diets, are major factors in MetS
prevalence and etiology,22,23 but no study, to our knowledge,
has examined how urban-rural differences may affect the
relationship between PAI-1 and MetS.
Here, we present a multivariate analysis of MetS and PAI-1,
using cardiovascular risk factor data from 3331 men and
women in Ghana from both urban and rural locales. We assess
the correlational architecture of MetS risk factors and
estimate their potential relevance to thrombotic endpoints
by using strength and independence of association with PAI-1
as a proxy. Because correlational analyses do not require any
assumptions of direction of effect, they are well suited for the
study of metabolic systems.24 Partial correlations in particular
can distinguish independent (and possibly direct) interactions
among risk factors from merely incidental associations. In
addition, we assess the possibility of nonlinear relationships
among risk factors, such as at the extremes of their
distributions, which may be especially pertinent to clinical
outcomes. Throughout, we evaluate how the patterns of
association we observe may be inﬂuenced by differences in
sex and environment (urban vs rural), both of which have been
shown to affect cardiovascular disease risk.25,26 The over-
riding goal of this study was to assess the extent to which
PAI-1 may play a central or connecting role in the diagnosis of
MetS.
Methods
Study Population
Participants were recruited from Sunyani, the capital of the
Brong Ahafo region of Ghana (population 250 000 as of the
2012 census), and from surrounding rural villages of fewer
than 5000 people. Urban recruitment occurred from 2002
to 2007. Rural participants were recruited in 2008.
Participants learned about the study at public venues,
including local churches and markets. Individuals <18 years
of age or who were ﬁrst- or second-degree relatives of
someone already enrolled in the study were excluded.
Participants provided information by in-person interviews
regarding their medical histories and other demographic
and socioeconomic factors, including education level,
smoking status, alcohol consumption, and current medica-
tions. All participants provided informed consent. Institu-
tional review boards at Dartmouth College (Hanover, NH),
Vanderbilt University (Nashville, TN), and Regional Hospital,
Sunyani approved all protocols.
Anthropometric Measurements and Biochemical
Analyses
The mean of 2 measurements for both systolic blood pressure
(SBP) and diastolic blood pressure (DBP) was calculated.
Blood was drawn between 8:00 and 10:00 AM, after a fast
≥8 hours, and used to assess fasting glucose, fasting lipids,
and PAI-1 levels. Glucose was measured from blood drops
using a SureStep monitor by LifeScan (Milpitas, CA). Total
cholesterol (TC), triglycerides (TG), and HDL levels were
measured in plasma. PAI-1 antigen was measured using an
enzyme-linked immunoassay (Biopool AB, Umea, The
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Netherlands). Here, only total PAI-1 was measured (compris-
ing free PAI-1 as well as its complexes with plasminogen
activators), given that the short half-life of the active molecule
in plasma makes it less useful for studies of chronic disease.
Body mass index (BMI) was calculated with weight and height
measurements (kg/m2).
Study Variables
Five categorical metabolic risk factors (hypertriglyceridemia,
low HDL, hypertension, hyperglycemia, and obesity) were
deﬁned according to the updated National Cholesterol
Education Program Adult Treatment Panel-III (NCEP ATP-III)
criteria,27 as follows: TG ≥150 mg/dL; HDL <40 mg/dL in
males or <50 mg/dL in females; SBP and DBP ≥130/
85 mm Hg or on antihypertensive medication; fasting glu-
cose (GLUC) ≥100 mg/dL or on antidiabetic medication; and
BMI ≥30. None of the study participants reported taking
statins. Mean arterial pressure (MAP) was calculated using
the formula: MAP=DBP+[(SBPDBP)/3], which approximates
the average arterial pressure during a single cardiac cycle.
Because MAP has been shown to predict future MetS more
accurately than SBP, DBP, or pulse pressure,28 it was used
in the correlational analyses. Pearson’s correlation coefﬁ-
cients and tests of correlational homogeneity are sensitive
to deviations from normality.29,30 Quantitative variables used
in the correlational analyses were therefore log-transformed
after observing that this improved approximations to
normality (using the Shapiro-Wilk test as a criterion). For
clarity of presentation, however, mention in the text does
not reﬂect these transformations (eg, as “ln-glucose” or “ln-
PAI-1,” etc).
For calculating prevalence of MetS, the study participants
for whom no data were missing (N=2220) and who had at
least 3 of the 5 conditions (as per the NCEP ATP-III
guidelines1) were deemed cases. The missing data for 1111
participants (598 urban, 513 rural) resulted from a supply
failure for HDL cholesterol assay during the collection
process.
Statistical Analyses
Prevalence rates of MetS were age-standardized to the World
Health Organization 2000–2025 standard population using
recommended age bins that pertained to our data (18–24,
25–34, 35–44, 45–54, and ≥55 years-old).31,32 Relative risks
(RRs) of MetS (for urban vs rural and female vs male) were
also estimated. To check for possible bias in the participants
with missing HDL data versus complete cases, the age-
adjusted means and variances of all other variables were
compared (by t test and Levene’s test, respectively) for both
groups.
Pair-wise correlations between BMI, MAP, GLUC, TG, HDL,
and PAI-1 were calculated, using the residuals after linear
regression on age, sex, and residence. Pair-wise correlations
were also calculated separately for (1) individuals stratiﬁed by
residence (after age and sex adjustment) and (2) individuals
stratiﬁed by sex (after age and residence adjustment). Tests
for homogeneity of correlation between groups (ie, urban vs
rural, male vs female) were conducted by t test after Fisher
transformation of correlation coefﬁcients.33 For every pair of
variables in the set of BMI, MAP, GLUC, TG, HDL, and PAI-1,
partial correlations were calculated controlling for the
remaining variables in the set, after which the above analyses
were repeated. For clarity, only these higher-order partial
correlations are referred to as “partial correlations” in the
text, although all correlations in this study are controlled for
age and sex and/or residence.
The following approach was used to assess visually
whether the strengths of association between MetS traits
(BMI, MAP, GLUC, TG, and HDL) and PAI-1 were consistent
over the entirety of their respective ranges, and to identify
patterns of nonlinear association: (1) Age-, sex-, and
residence-adjusted regression residuals of the ﬁve MetS
traits were standardized, ranked in ascending order, and
paired with corresponding standardized PAI-1 values; (2) the
25th percentile, median, and 75th percentile of PAI-1
(period=100) were plotted against the corresponding
median (period=100) of each MetS trait; (3) smooth curves
of the plots were generated, using a cubic spline
method. Brieﬂy, for n observations, where ~xi is the ith
standardized median (period 100) of a risk factor, i2[1,
n99], and ~Pi the corresponding quantile value of PAI-1,
such that ~Pi ¼ lð~xiÞ, the smoothing function l^ estimated l
by minimizing
Xn99
i¼1
~Pi  l^ð~xiÞ
 2þk
Z x2
x1
l^00ð~xÞ2d~x
The ﬁrst term represents the sum of squares error and the
second term the penalty for “roughness.” The parameter k
controls the bias-variance trade-off and was set to 10.34 PAI-1
quartiles were used in these analyses rather than mean values
to minimize the inﬂuence of outliers caused by the charac-
teristic kurtosis of the PAI-1 distribution, and to gain insight
into whether PAI-1 levels at upper or lower quartiles associate
differently with changes in the other risk factors.
For further analysis, an ordinal variable, deﬁned as the
number of conditions with which an individual was diag-
nosed (ie, 0 through 5), was created to augment the
dichotomous characterization of MetS (ie, as the presence or
absence of at least 3 conditions). Mean PAI-1 was calculated
for each of these groups, using the standardized age-, sex-,
and residence-adjusted residuals. The association between
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MetS progression and PAI-1 was then assessed in 2 ways.
First, the number of MetS conditions was modeled as a
function of PAI-1, using ordinal regression (with cumulative
logit link), adding age, sex, and residence as covariates. PAI-
12 was then added as an explanatory variable, and the ﬁt of
the quadratic versus the linear model was compared using
the likelihood ratio test. Second, mean PAI-1 levels were
compared by t test for each sequential pair of groups (ie, 0
vs 1 conditions, 1 vs 2, etc). A curve was also ﬁtted to the
PAI-1 means using polynomial regression (quadratic). Statis-
tical analyses were performed using JMP Pro (12.1; SAS
Institute Inc., Cary, NC), STATA (12; StataCorp LP, College
Stattion, TX), and R software (3.2; R Foundation for
Statistical Computing, Vienna, Austria).
Results
Of the 3331 participants in this study, 2276 (68%) were
urban residents, of whom 1298 (57%) were female and 978
male. Of the 1055 rural residents, 583 (55%) were female
and 472 male. Ages ranged from 18 to 99 and were
similarly distributed among urban and rural men and women
(P=0.23, Kruskal–Wallis test). In analyses that depended on
the total number of categorical risk factors, participants
with missing data were excluded, lowering the sample size
to 2220. The decrease in sample size resulted from the
lack of supplies for testing HDL cholesterol during the
collection process. However, the distributions of measured
variables between participants with and without missing
data were not signiﬁcantly different (Table S1), consistent
with the sporadic and random timing of the supply
shortages. Age-standardized MetS prevalence by group
and summary data of associated variables are presented
in Table 1 and Figure S1.
Prevalence and RR of MetS
Male and female urban residents had a signiﬁcantly higher RR
of MetS than their rural counterparts (1.61 with 95% CI, 1.02–
2.53, and 1.72 with 95% CI, 1.28–2.3, males and females,
Table 1. Prevalence of MetS and Its Component Risk Factors Among 2220 Urban and Rural Men and Women From Brong Ahafo,
Ghana
Males Females
Urban Rural Urban Rural
N=721 N=225 N=957 N=317
MetS* 0.126 (0.102, 0.151) 0.078 (0.043, 0.113) 0.214 (0.188, 0.240) 0.112 (0.077, 0.147)
Obesity 0.065 (0.049, 0.086) 0.00 (0.00, 0.017) 0.265 (0.238, 0.294) 0.050 (0.031, 0.080)
Hypertension 0.130 (0.108, 0.157) 0.111 (0.076, 0.159) 0.097 (0.080, 0.118) 0.088 (0.062, 0.125)
Hyperglycemia 0.413 (0.378, 0.450) 0.267 (0.213, 0.328) 0.389 (0.358, 0.420) 0.293 (0.246, 0.346)
High TG 0.239 (0.209, 0.271) 0.173 (0.129, 0.228) 0.315 (0.286, 0.345) 0.293 (0.246, 0.346)
Low HDL-C 0.437 (0.401, 0.473) 0.391 (0.330, 0.456) 0.588 (0.557, 0.619) 0.612 (0.557, 0.664)
HDL-C indicates high-density lipoprotein cholesterol; MetS, metabolic syndrome; TG, triglycerides.
*Prevalence was age-standardized to the World Health Organization 2000–2025 standard population; N=sample size of participants for whom no data were missing; in parentheses: 95%
CIs.
Figure 1. Relationship between the total number of risk factor
diagnoses and mean PAI-1 concentrations. Horizontal axis: 2220
participants from the Brong Ahafo region of Ghana were grouped
by number of risk factor conditions (obesity, hypertension,
hyperglycemia, hypertriglyceridemia, and low HDL); 22 partici-
pants had all 5; 573 had 4; 473 had 3; 376 had 2; 300 had 1; and
573 had none. Vertical axis: For each group, mean standardized
ln-PAI-1 concentrations (adjusted for age, sex, and urban/rural
residence) are depicted with 95% CIs. P values above horizontal
brackets are for t tests comparing the means of adjacent groups.
PAI-1 was normally distributed within each group (Shapiro-
Wilk test; P>0.05). The quadratic ﬁt to the means is also depicted
(R2=0.996). HDL indicates high-density lipoprotein choles-
terol; MetS, metabolic syndrome; PAI-1, plasminogen activator
inhibitor 1.
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respectively). Urban women, who had the highest prevalence
of obesity among all groups (26.5%), also had the highest age-
standardized prevalence of MetS (21.4%; Table 1), with an RR
of 1.68 (CI, 1.36–2.07) compared to urban men (P<0.0001),
and 1.72 compared to rural women (P=0.0002). Among rural
participants, risk of MetS did not differ by sex.
Relationship Between PAI-1 and Number of MetS
Conditions
Mean PAI-1 (log-normalized and adjusted for age, sex, and
residence) rose exponentially as the number of MetS risk
factors increased linearly. The quadratic ﬁt to the means was
virtually perfect (R2=0.996). Among participants who had at
least 1MetS risk factor, mean PAI-1 increased signiﬁcantly with
each additional condition, with the most signiﬁcant increase
occurring when the number of conditions increased from 2 to 3,
consistent with the NCEP ATP-III deﬁnition (Figure 1). Ordinal
polynomial regression was also used to model the number of
MetS risk factors as a function of PAI-1. The improvement of the
quadratic ﬁt over the linear ﬁt was highly signiﬁcant (P<1013),
conﬁrming the strong exponential relationship between the
logarithm of PAI-1 level and number of MetS criteria.
Pair-wise Correlations of Risk Factors
All pair-wise correlations between risk factors adjusted for age,
sex, and residence were statistically signiﬁcant (P<0.0001),
except for the correlation between MAP and HDL (Table 2 and
Figure 2). Seven of 15 correlations were at least 0.20 in
magnitude: BMI-PAI-1; BMI-TG; BMI-MAP; TG-PAI-1; TG-HDL;
MAP-PAI-1; and GLUC-PAI-1. The above analysis was repeated
after stratifying participants by urban versus rural residence
and adjusting for age and sex. Of the 5 pair-wise correlations
with PAI-1, 3 were signiﬁcantly stronger in the urban popula-
tion: BMI (P=4.99109); GLUC (P=9.99104); and TG
(P=2.19103; Table 2 and Figure 2). Among pair-wise corre-
lations that did not include PAI-1, only 2 of 10 pairs were
signiﬁcantly different: BMI-HDL (P=0.047) and BMI-TG
(P=0.012), with both correlations again stronger in the urban
population (Table 2 and Figure 2). When participants were
stratiﬁed by sex, no P value for homogeneity of correlation was
smaller than 0.01 (Table 3 and Figure 2). Of the 3 signiﬁcant at
the 0.05 level, the GLUC-PAI-1 correlation was higher in women
than in men, and the correlations of both BMI and PAI-1 with
MAP were higher in men.
Pair-wise Partial Correlations of Risk Factors
Partial correlations between pairs of risk factors (including
PAI-1) that controlled for all other risk factors (in addition to
age and sex and/or residence, as above) were calculated to
assess strengths of independent association. All partial
correlations were statistically signiﬁcant, with 4 greater than
0.20 in magnitude: BMI-PAI-1; TG- PAI-1; BMI-MAP; and TG-
HDL (Table 4 and Figure 3). Three of 15 partial correlations
were signiﬁcantly different between urban and rural residents
(BMI-PAI-1, P=0.0002; GLUC-PAI-1, P=0.001; and BMI-GLUC,
P=0.005), with the stronger correlations in the urban group
(Table 4 and Figure 3). Only 1 of 15 partial correlations was
signiﬁcantly different between men and women (GLUC-PAI-1,
P=0.023; Table 5 and Figure 3). The partial correlational
analyses were repeated for MetS risk factors without PAI-1
and yielded comparable results (Tables S2 through S4).
Figure 2. Strengths of correlation between cardiovascular risk
factors associated with metabolic syndrome and their differences
by sex and urban/rural residence. A, Colors in the heat map
reﬂect the magnitude of correlation between risk factors adjusted
for age, sex, and residence. In (B), shading reﬂects the statistical
signiﬁcance of differences in correlation by sex (below diagonal,
purple) and residence (above diagonal, green). BMI indicates body
mass index; GLUC, glucose; HDL, high-density lipoprotein
cholesterol; MAP, mean arterial pressure; PAI-1, plasminogen
activator inhibitor 1; TG, triglycerides.
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Relationship Between PAI-1 Quartiles and MetS
Risk Factors
Consistent with the strong correlations, median PAI-1
increased most with BMI and TG, from 0.5 SD below the
mean to 1.0 SD above (Figure 4). Notably, median PAI-1 did
not vary when BMI was less than 1 SD below its mean. The
relationship between PAI-1 quartiles and glucose displayed an
abrupt shift at a glucose value of +1.5 SD, from strongly
positive to ﬂat (Figure 4). The moving quartiles of PAI-1 were
also evaluated for data stratiﬁed by sex and residence
(Figure 5), revealing pronounced differences in the urban/
rural PAI-1 quartiles. In contrast, the male-female trajectories
of PAI-1 were almost indistinguishable, regardless of risk
factor. The signiﬁcantly different correlations by sex observed
for PAI-1-MAP and PAI-1-GLUC, however, were likely reﬂected
in the slight discordances at the right tails of their distribu-
tions (Figure 5).
To complement the partial correlational analyses, which
assessed the independence of association among risk factors,
PAI-1 quartiles were also plotted against each risk factor after
adjustment for all others (Figure 4). The relationship of PAI-1
quartiles with all variables except BMI changed qualitatively
with these additional adjustments. The most consistent
difference was that independent associations with PAI-1 were
much weaker when risk factors were below their means
(Figure 4). Over their entire ranges, MAP and HDL had the
weakest independent associations with PAI-1, corresponding
to weak partial correlations (r<0.10). In contrast, the
independent association between glucose and median PAI-1
was relatively strong, despite a similarly weak GLUC-PAI-1
partial correlation (r<0.10; Figure 4).
Discussion
A much-discussed topic has been whether the clustering of
factors associated with MetS increases total cardiovascular
disease risk in an additive or exponential way.35–38 If, as
observed here, PAI-1 increases exponentially as MetS diag-
nostic conditions increase linearly, then the question of
whether MetS is “more than the sum of its parts” can be
reduced, in part, to the clinical consequences of elevated
PAI-1. Although the added value of using elevated PAI-1 as a
prognostic indicator of adverse cardiac events has been
debated,39 its connection with increased cardiovascular risk
has been demonstrated convincingly by many clinical and
epidemiological studies.7,40–44 Our results therefore support
the basis of MetS as a clinical entity with distinct outcomes.
We also observed the most signiﬁcant increase in PAI-1 when
the number of risk factors increased from 2 to 3, which
supports the current NCEP ATP-III deﬁnition.
We found that the correlations between PAI-1 and the
factors that deﬁne MetS (BMI, MAP, HDL, TG, and GLUC) were
generally stronger than the correlations between the factors
themselves. Given that MetS is essentially deﬁned by the
association of multiple risk factors, our results raise the
question of whether PAI-1 should also be incorporated into its
deﬁnition and diagnosis. For example, the strongest pair-wise
correlations that included BMI, TG, or glucose were all with
PAI-1. Moreover, this pattern did not change when we
controlled for the inﬂuence of other factors, suggesting an
independent role for PAI-1 in the clinical pathology of MetS.
Figure 3. Strengths of partial correlation between cardiovascu-
lar risk factors associated with metabolic syndrome, including
PAI-1, and their differences by sex and urban/rural residence. A,
Colors in the heat map reﬂect the magnitude of partial correlation
between risk factor pairs adjusted for all remaining risk factors, as
well as age, sex, and residence. In (B), shading reﬂects the
statistical signiﬁcance of differences in partial correlation by sex
(below diagonal, purple) and residence (above diagonal, green).
BMI indicates body mass index; GLUC, glucose; HDL, high-density
lipoprotein cholesterol; MAP, mean arterial pressure; PAI-1,
plasminogen activator inhibitor 1; TG, triglycerides.
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Because PAI-1 plays a direct biochemical role in thrombo-
sis, each MetS factor’s strength of correlation with PAI-1 may
be indicative of its relevance to MetS-related cardiac events.
Partial correlations with PAI-1 may be particularly relevant,
because independent associations are more likely to reﬂect
direct biochemical and physiological connections. In this
regard, the strongest partial correlation we observed, that
between PAI-1 and BMI, is consistent with the known
biological mechanism of PAI-1 release from adipocytes.
Adipokines also amplify PAI-1 expression through inﬂamma-
tory pathways,45 whereas PAI-1 itself may promote accumu-
lation of visceral fat,46 perhaps by mediating insulin
signaling.47–49 The second strongest partial correlation we
observed was between PAI-1 and TG, likely inﬂuenced by the
fact that the PAI-1 promoter is responsive to VLDL, which
transports TG.50 A similar connection exists between PAI-1
and the renin-angiotensin system, involved in hypertension.51
None of the partial correlations among the 5 MetS risk
factors varied by sex or urban/rural environment when
PAI-1 was excluded from analyses, despite differences in
the underlying male/female and urban/rural risk factor
distributions. This correlational homogeneity among con-
ventional MetS criteria suggests that the relationships
among risk factors are likely stable over a wide range of
values and fairly insensitive to differences in physiological
background, environment, and lifestyle. In contrast, the
positive correlation of BMI, TG, and glucose with PAI-1 was
markedly stronger in the urban population. To the extent
that elevated PAI-1 increases the risk of thrombotic
endpoints, then, it is possible that high BMI, TG, and
glucose confer greater risk in urban than in rural environ-
ments. It is therefore likely that undeﬁned aspects of the
urban environment inﬂuence the nature of the relationships
between adiposity, fasting glucose, TG, and PAI-1. In
addition to obesity, factors such as stress and nutrient-
poor diets have been shown to inﬂuence PAI-1 expression
directly in animal models,52,53 making these possible
candidates as effect modiﬁers.
Figure 4. PAI-1 quartiles as a function of standardized MetS risk factor values. A, Medians (solid) and ﬁrst and third quartiles (dotted) of
standardized ln-PAI-1 after all data were adjusted for age, sex, and residence; in (B), data were further adjusted for the other risk factors. Period
for quartiles=100. Data smoothed using cubic spline. BMI indicates body mass index; GLUC, glucose; HDL, high-density lipoprotein cholesterol;
MAP, mean arterial pressure; MetS, metabolic syndrome; TRIG, triglycerides.
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Our results show that important physiological connections
can be underestimated by a single correlation coefﬁcient. For
example, the correlation between glucose and PAI-1 was likely
the result of 2 different patterns of association, which shifted at
higher glucose values. Importantly, when glucose was less than
2 SDs above the mean, its relationship with PAI-1 quartiles
was comparable to the stronger BMI-PAI-1 and TG-PAI-1
relationships. Similar analyses of PAI-1 quartiles using the
residuals of the partial correlations conﬁrmed this. The strong,
independent connection over most of the normal glucose range
may, in part, reﬂect increasing insulin resistance, which
ampliﬁes PAI-1 expression by accelerating the release of free
fatty acids.54
Although we could not ﬁnd similar studies with which to
compare our higher-order partial correlations directly, a
recent meta-analysis of 85 000 people (of whom 7.8% were
African American and the remainder European) reported
pair-wise correlations between MetS risk factors adjusted
for age and sex.55 Among all 15 pair-wise correlations we
assessed, only BMI-GLUC and BMI-HDL here (adjusted for
age, sex, and residence) fell outside of the 95% CIs
reported by the meta-analysis. That study reported r=0.33
for BMI-HDL and r=0.28 for BMI-GLUC, in contrast to our
results of r=0.15 and 0.15, respectively. With respect to
HDL, this may be because many Ghanaians with normal
BMI had low HDL. For example, 49% of participants with
BMI below the obesity threshold had low HDL, and 25% of
the participants with at least 1 risk factor had low HDL as
the isolated condition. There may therefore be aspects
of the Ghanaian environment, perhaps including diets, that
contribute to low HDL in the absence of other risk factors.
Speculation regarding the difference in the GLUC-PAI-1
correlation is more difﬁcult, but we note that a previous
study found a difference in the insulin-PAI-1 relationship
between African and European women, which might provide
some insight.56
MetS was signiﬁcantly more prevalent in the urban
population than the rural, and urban women were partic-
ularly at risk. Excess adiposity is generally considered the
primary cause of MetS,57 and the urban women had, by far,
Figure 5. PAI-1 quartiles as a function of standardized MetS risk factor values, by sex and urban/rural residence. A, Medians (solid) and ﬁrst
and third quartiles (dotted) of standardized ln-PAI-1 values (period=100) for men (blue) and women (red); data adjusted for age and urban/rural
residence, and smoothed using cubic spline. B, Medians (solid) and ﬁrst and third quartiles (dotted) of standardized ln-PAI-1 values (period=100)
for urban (purple) and rural (green) participants; data adjusted for age and sex, and smoothed using cubic spline. BMI indicates body mass index;
GLUC, glucose; HDL, high-density lipoprotein cholesterol; MAP, mean arterial pressure; MetS, metabolic syndrome; TRIG, triglycerides.
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the highest prevalence of obesity. Nonetheless, the partial
correlations between BMI and the other MetS risk factors
in our study populations were surprisingly weak. Whereas
cause cannot be inferred from correlation, it can be ruled
out by the absence of correlation; therefore, the hypoth-
esized causal connection between excess adiposity and
MetS in African populations may not be straightforward.
Simultaneous factors of susceptibility are probably involved.
It is true that BMI serves as a somewhat crude variable for
adiposity, in part because it does not necessarily reﬂect the
distribution of body fat (eg, subcutaneous vs abdominal) on
which the metabolic properties of adipocytes may
depend.58 Although waist circumference (WC) has often
replaced BMI in studies of MetS, because increased
abdominal fat is highly indicative of the MetS proﬁle, it is
not clear whether abdominal fat makes a greater contribu-
tion to total plasma PAI-1 than subcutaneous fat, particu-
larly because stores of subcutaneous fat are typically much
larger.59–61 Moreover, some evidence indicates that WC
may not be an effective measure of abdominal fat mass in
African populations,62 and that, even when measured
accurately, abdominal fat may have a weaker relationship
with plasma PAI-1 in Africans than in European-descent
populations.59,63
The weak connection between obesity and MetS was
particularly evident among rural males. Their age-standardized
prevalence of MetS (7.8%) was unexpectedly high, despite no
rural male participant’s BMI being above the obesity thresh-
old. Whereas “metabolically obese” individuals of normal
weight are not uncommon in some populations (eg, South
Asians),64,65 often MetS without obesity reﬂects insulin
resistance caused by factors other than excess adiposity.66
However, 40% of the rural men who met the diagnostic criteria
of MetS in our study did not have hyperglycemia in addition to
hypertension and/or dyslipidemia (low HDL or high TG),
making it unlikely that they were insulin resistant. MetS in the
absence of obesity is also associated with the distribution of
adipose tissue, which varies among populations56,62,67,68 and
may affect PAI-1 expression.59 Thus, how comparable our
rural participants are to others diagnosed with MetS is
unclear, either from the standpoint of pathophysiology or
clinical prognosis.
Some limitations of our study need to be acknowledged.
The cross-sectional design of our study reduced our ability to
elucidate causal relationships. Also, though our total sample
size was relatively large, power was somewhat diminished
after participants were stratiﬁed by sex and residence.
Nonetheless, we identiﬁed highly signiﬁcant ﬁndings in many
of these stratiﬁed analyses. Our direct comparisons of higher-
and lower-order partial correlations were further complicated
by asymmetric power, owing to different numbers of adjust-
ments. Additionally, though we performed these adjustments
Table 5. Pearson Partial Correlation Coefﬁcients Between Cardiovascular Risk Factors Associated With MetS, Including PAI-1, by
Sex
Trait 1 Trait 2
Females Males
Homogeneity of
Correlation P Valuer CI N P Value r CI N P Value
BMI PAI-1 0.35 (0.30, 0.40) 1274 <0.0001 0.29 (0.23, 0.34) 946 <0.0001 0.0814
BMI GLUC 0.02 (0.03, 0.08) 1274 0.4626 0.07 (0.00, 0.13) 946 0.0430 0.2920
BMI HDL 0.08 (0.13, 0.02) 1274 0.0052 0.11 (0.17, 0.05) 946 0.0008 0.4682
BMI MAP 0.21 (0.16, 0.26) 1274 <0.0001 0.26 (0.20, 0.32) 946 <0.0001 0.2487
BMI TG 0.07 (0.01, 0.12) 1274 0.0142 0.09 (0.02, 0.15) 946 0.0067 0.6497
GLUC PAI-1 0.14 (0.09, 0.20) 1274 <0.0001 0.05 (0.02, 0.11) 946 0.1410 0.0233
GLUC HDL 0.07 (0.12, 0.01) 1274 0.0128 0.08 (0.14, 0.01) 946 0.0202 0.8921
GLUC MAP 0.06 (0.01, 0.12) 1274 0.0241 0.10 (0.04, 0.17) 946 0.0014 0.3414
GLUC TG 0.10 (0.04, 0.15) 1274 0.0006 0.07 (0.00, 0.13) 946 0.0447 0.4765
HDL PAI-1 0.09 (0.14, 0.03) 1274 0.0020 0.01 (0.08, 0.05) 946 0.6987 0.0842
HDL MAP 0.13 (0.07, 0.18) 1274 <0.0001 0.12 (0.05, 0.18) 946 0.0004 0.7427
HDL TG 0.20 (0.25, 0.14) 1274 <0.0001 0.25 (0.31, 0.19) 946 <0.0001 0.2210
MAP PAI-1 0.07 (0.02, 0.13) 1274 0.0094 0.12 (0.06, 0.19) 946 0.0001 0.2363
MAP TG 0.07 (0.01, 0.12) 1274 0.0134 0.09 (0.02, 0.15) 946 0.0078 0.6872
TG PAI-1 0.22 (0.17, 0.27) 1274 <0.0001 0.25 (0.19, 0.31) 946 <0.0001 0.4270
r=Pearson partial correlation coefﬁcient, calculated using residuals after adjustment for age and residence, by sex; CI=95% conﬁdence interval; P value=probability of r if true partial
correlation is zero; Homogeneity of Correlation P value=probability of these data if true partial correlation is equal for men and women. BMI indicates body mass index; GLUC, glucose;
HDL, high-density lipoprotein cholesterol; MAP, mean arterial pressure; MetS, metabolic syndrome; PAI-1, plasminogen activator inhibitor 1; TG, triglycerides.
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to distinguish direct interactions among risk factors from
merely incidental associations, we could only control for
conventional risk factors, and, moreover, these risk factors
have generally been deﬁned on the bases of European
studies.69,70
Our study explored the role of PAI-1 in MetS from multiple
perspectives in an understudied population. Although urban
residence and sex had dramatic effects on the mean values of
cardiovascular risk factors, our partial correlational analyses
revealed that the relationships among the factors used to
diagnose MetS are remarkably stable. In contrast, the
relationships between these factors and PAI-1 were more
sensitive to such differences. Thus, urban-rural differences
impacted not only MetS prevalence, but also patterns of
clustering and association with PAI-1. Identifying the speciﬁc
factors responsible for these phenomena should provide
unique insight into MetS etiology and, where modiﬁable, could
inform public health measures. The patterns we have
identiﬁed, such as the exponential relationship between mean
PAI-1 and MetS diagnostic conditions, and the nonlinear
relationships between PAI-1 and some of the MetS risk
factors, improve our understanding of how MetS may mediate
cardiovascular disease risk, although generalizability to other
populations will require further study. In summation, we
provide evidence that the prothrombotic state may be more
than a mere epiphenomenon of MetS, possibly playing a
major role in its etiology and its clinical sequelae.
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Table S1. Comparison of risk factor distributions between participants with missing HDL 
measurements (N=1111) and those with full data (N=2220), by sex and residence. 
Group 
N, 
complete/ 
missing 
Trait 
standardized 
mean difference 
95% 
CIL 
95% 
CIU 
p-value (t-
test) 
p-value 
(Levene's 
test) 
URBAN 
MALES 
721/257 
PAI-1 -0.026 -0.169 0.117 0.721 0.132 
BMI 0.064 -0.079 0.206 0.381 0.956 
MAP 0.092 -0.031 0.216 0.143 0.299 
TRIG -0.106 -0.230 0.018 0.094 0.307 
GLUC -0.047 -0.170 0.077 0.461 0.76 
RURAL 
MALES 
225/247 
PAI-1 0.029 -0.153 0.210 0.756 0.725 
BMI -0.124 -0.305 0.057 0.178 0.216 
MAP 0.143 -0.038 0.324 0.122 0.677 
TRIG 0.083 -0.098 0.265 0.368 0.204 
GLUC 0.031 -0.150 0.213 0.734 0.428 
URBAN 
FEMALES 
957/341 
PAI-1 -0.134 -0.258 -0.011 0.033 0.255 
BMI -0.026 -0.150 0.098 0.68 0.186 
MAP 0.040 -0.103 0.182 0.586 0.011 
TRIG -0.129 -0.273 0.014 0.077 0.906 
GLUC -0.126 -0.268 0.017 0.084 0.485 
RURAL 
FEMALES 
317/266 
PAI-1 0.017 -0.147 0.180 0.841 0.867 
BMI 0.084 -0.079 0.248 0.311 0.057 
MAP 0.006 -0.157 0.170 0.938 0.242 
TRIG 0.182 0.019 0.346 0.029 0.853 
GLUC 0.116 -0.047 0.279 0.164 0.916 
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 Table S2. Pearson partial correlation coefficients between the five components of the metabolic syndrome. (PAI-1 excluded from 
analysis.)  
Trait  Trait  r CI N p-value 
MAP BMI 0.27 (0.23, 0.31) 2220 <.0001 
HDL BMI -0.11 (-0.15, -0.07) 2220 <.0001 
HDL MAP 0.12 (0.07, 0.16) 2220 <.0001 
TG BMI 0.16 (0.12, 0.20) 2220 <.0001 
TG MAP 0.11 (0.07, 0.15) 2220 <.0001 
TG HDL -0.24 (-0.28, -0.20) 2220 <.0001 
GLUC BMI 0.08 (0.04, 0.12) 2220 0.0002 
GLUC MAP 0.09 (0.05, 0.13) 2220 <.0001 
GLUC HDL -0.08 (-0.12, -0.04) 2220 <.0001 
GLUC TRIG 0.11 (0.07, 0.15) 2220 <.0001 
r = Pearson partial correlation coefficient, calculated using residuals after adjustment for age, sex, and residence; 
CI = 95% confidence interval;  
p-value = probability of r if true partial correlation is zero.  
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Table S3. Pearson partial correlation coefficients between the five components of the metabolic syndrome, by urban or rural 
residence. (PAI-1 excluded from analysis.) 
  Rural  Urban Homogeneity 
of Correlation 
p-value 
Trait 1 Trait 2 r CI N p-value   r CI N p-value 
MAP BMI 0.24 (0.16, 0.32) 542 <.0001  0.28 (0.24, 0.33) 1678 <.0001 0.3335 
HDL BMI -0.06 (-0.14, 0.02) 542 0.1631  -0.14 (-0.19, -0.09) 1678 <.0001 0.1083 
HDL MAP 0.12 (0.04, 0.20) 542 0.0042  0.12 (0.07, 0.17) 1678 <.0001 0.9314 
TG BMI 0.09 (0.01, 0.18) 542 0.0297  0.19 (0.14, 0.24) 1678 <.0001 0.0430 
TG MAP 0.16 (0.07, 0.24) 542 0.0002  0.09 (0.04, 0.13) 1678 0.0004 0.1449 
TG HDL -0.28 (-0.36, -0.20) 542 <.0001  -0.23 (-0.27, -0.18) 1678 <.0001 0.2250 
GLUC BMI 0.13 (0.05, 0.21) 542 0.0021  0.05 (0.01, 0.10) 1678 0.0245 0.1180 
GLUC MAP 0.11 (0.02, 0.19) 542 0.0116  0.08 (0.03, 0.13) 1678 0.0011 0.5601 
GLUC HDL -0.09 (-0.17, -0.01) 542 0.0356  -0.08 (-0.13, -0.03) 1678 0.0011 0.8230 
GLUC TRIG 0.12 (0.04, 0.20) 542 0.0044  0.11 (0.06, 0.15) 1678 <.0001 0.7341 
 
r = Pearson partial correlation coefficient, calculated using residuals after adjustment for age and sex, by residence; 
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CI = 95% confidence interval;  
p-value = probability that the true partial correlation is zero; 
Homogeneity of Correlation p-value = probability of these data if true partial correlation is equal for urban & rural. 
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Table S4. Pearson partial correlation coefficients between the five components of the metabolic syndrome, by sex. (PAI-1 excluded 
from analysis.)  
  Females  Males Homogeneity 
of Correlation 
p-value 
Trait 1 Trait 2 r CI N p-value   r CI N p-value 
MAP BMI 0.26 (0.20, 0.31) 1274 <.0001  0.31 (0.25, 0.37) 946 <.0001 0.1710 
HDL BMI -0.12 (-0.17, -0.07) 1274 <.0001  -0.12 (-0.18, -0.05) 946 0.0003 0.9642 
HDL MAP 0.13 (0.07, 0.18) 1274 <.0001  0.11 (0.05, 0.18) 946 0.0004 0.7842 
TG BMI 0.16 (0.11, 0.21) 1274 <.0001  0.17 (0.11, 0.23) 946 <.0001 0.7575 
TG MAP 0.09 (0.03, 0.14) 1274 0.0016  0.12 (0.06, 0.18) 946 0.0002 0.4210 
TG HDL -0.22 (-0.27, -0.17) 1274 <.0001  -0.26 (-0.32, -0.20) 946 <.0001 0.3481 
GLUC BMI 0.08 (0.02, 0.13) 1274 0.0060  0.08 (0.02, 0.15) 946 0.0106 0.8846 
GLUC MAP 0.08 (0.02, 0.13) 1274 0.0074  0.11 (0.05, 0.17) 946 0.0006 0.4021 
GLUC HDL -0.09 (-0.14, -0.03) 1274 0.0023  -0.08 (-0.14, -0.01) 946 0.0189 0.8331 
GLUC TRIG 0.13 (0.08, 0.19) 1274 <.0001  0.08 (0.02, 0.14) 946 0.0141 0.2184 
 
r = Pearson partial correlation coefficient, calculated using residuals after adjustment for age and residence, by sex; 
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CI = 95% confidence interval;  
p-value = probability of r if true partial correlation is zero; 
Homogeneity of Correlation p-value = probability of these data if true partial correlation is equal for men & women.  
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Figure S1. Proportions of participants with N∈[0,5] component risk factors of the 
metabolic syndrome, by sex and environment. Lengths of rectangles represent the percentage 
of participants with N risk factors within each labeled group: Total= all 2220 participants for 
whom no data were missing; UM = urban males; UF= urban females; RM= rural males; RF= 
rural females. Areas of rectangles for UM, UF, RM, RF represent proportions with respect to all 
2220 participants. 
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